Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,443.10 25.42 0.18%
TOPIX 1,169.21 2.66 0.23%
HANG SENG 22,757.27 61.26 0.27%

Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American



  Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3
  Trial and Two Pharmacology Studies at the American College of
  Neuropsychopharmacology (ACNP) Annual Meeting

Business Wire

NEW YORK -- December 03, 2012

Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting
data on cariprazine at the American College of Neuropsychopharmacology Annual
Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories,
Inc recently submitted a New Drug Application to the U.S. Food and Drug
Administration (FDA) for cariprazine for the treatment of schizophrenia and
the acute treatment of manic or mixed episodes associated with Bipolar I
disorder.

The cariprazine results will be announced in 3 poster presentations:

  * Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia:
    A Phase III, International, Randomized, Double-blind, Placebo-controlled
    Trial  (Poster 9: Wednesday, December 5 from 5:30 pm - 7:30 pm EST)
  * Cariprazine Exhibits Dopamine D[3] Receptor-Dependent Antidepressant-Like
    Activity in the Chronic Unpredictable Stress Model of Anhedonia (Poster
    12: Monday, December 3 from 5:30 pm - 7:30 pm EST)
  * Effects of Chronic Cariprazine Administration on Serotonin and Glutamate
    Receptor Subtypes (Poster 161: Monday, December 3 from 5:30 pm - 7:30 pm
    EST)

About Cariprazine

Cariprazine is an orally active and potent dopamine D[3]-preferring D[3 ]/D[2]
receptor partial agonist. Cariprazine has a low affinity at other receptor
sites such as 5-HT[2C], muscarinic, and adrenergic which have been associated
with adverse events.

Cariprazine was discovered by Gedeon Richter Plc and is licensed to Forest
Laboratories Inc., in the U.S. and Canada.

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.richter.hu) headquartered in Budapest/Hungary, is a
major pharmaceutical company in Central Eastern Europe, with an expanding
direct presence in Western Europe. Richter’s consolidated sales
were approximately EUR 1.1 billion (USD 1.5 billion) while its market
capitalization amounted to EUR 2.1 billion (USD 2.7 billion) in 2011. The
product portfolio of the Company covers almost all important therapeutic
areas, including gynecology, central nervous system and cardiovascular. Having
the largest R&D unit in Central Eastern Europe, the Company’s original
research activity focuses on CNS disorders. With its widely acknowledged
steroid chemistry expertise Richter is a significant player in the female
healthcare field worldwide. Richter is also active in the scope of biosimilar
product development.

About Forest Laboratories

Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track
record developing and marketing pharmaceutical products in the United States
have yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective and respiratory,
gastrointestinal, and pain management medicine. The Company’s pipeline, the
most robust in its history, includes product candidates in all stages of
development across a wide range of therapeutic areas. The Company is
headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update forward
looking statements contained in this release to reflect new information or
future events or developments.

Contact:

Forest Laboratories, Inc.
Frank J. Murdolo, 212-224-6714
Vice President - Investor Relations
Frank.Murdolo@frx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement